AI Article Synopsis
- - The introduction of the acellular pertussis vaccine into Canada's childhood immunization schedule in 1997-98 significantly decreased infant hospitalizations and ICU admissions for pertussis, with rates dropping from 165.1 to 33.6 per 100,000 population post-implementation.
- - Analysis of hospitalization data from 1981 to 2016 showed a 4.9 times lower risk of hospitalization and a 1.58 times lower risk of ICU admission in the period after the vaccine was introduced compared to before.
- - Despite the overall decline in hospitalizations, infants under 2 months still experienced the highest rates of pertussis-related hospital admissions, highlighting the continued vulnerability of this age group. *
Article Abstract
Objective: The acellular pertussis vaccine was introduced into the routine childhood immunization schedule across Canada in 1997-98 and adolescent booster doses were added between 1999 and 2005. We sought to assess the impact of these changes on infant pertussis hospitalizations and admissions to intensive care units (ICU) in Canada.
Methods: Hospitalizations with a primary diagnosis of pertussis were extracted from the Canadian Discharge Abstract Database (DAD) for cases with hospital discharge dates between 1981 and 2016 using relevant ICD-9 and ICD-10 codes. Only cases with age less than one year at time of admission were included. Disease severity was assessed by admission to ICU. Cases were categorized into two periods: pre-program implementation period (1981-1995) and the post-program implementation period (2006-2016). Incidence rates, risk ratios, and rate differences were calculated for each period and comparisons for the two periods were done using chi-squared and t-tests. Quasi Poisson analysis was used to investigate trends.
Results: When comparing the pre- and post-implementation periods, the average annual hospitalization rates for infants less than 1 year declined from 165.1 (95% CI 161.3, 168.9) to 33.6 (95% CI 31.6, 35.6) pertussis-related admissions per 100,000 population, with a corresponding reduction in the risk ratio of 4.9 (95% CI 4.6, 5.2). The risk of admission into an ICU was 1.58 times higher in the pre- versus post-implementation period while the highest reduction in average annual hospitalizations was 263.3 admissions per 100,000 population in infants 2 months of age. In the post-implementation period, infants less than 1 month of age had the highest average annual hospitalization rate at 126.6 (95% CI 113.1, 140.1) hospitalizations per 100,000 infants.
Conclusion: Infant pertussis hospitalizations have reduced greatly over time. Infants under 2 months of age remain the most at-risk age group for hospitalization and admission to ICU.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2018.10.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiological characteristics and prediction model construction of hand, foot and mouth disease in Quzhou City, China, 2005-2023.
Front Public Health
January 2025
Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Background: HFMD is a common infectious disease that is prevalent worldwide. In many provinces in China, there have been outbreaks and epidemics of whooping cough, posing a threat to public health.
Purpose: It is crucial to grasp the epidemiological characteristics of HFMD in Quzhou and establish a prediction model for HFMD to lay the foundation for early warning of HFMD.
Decreased vaccine coverage and waning immunity are cited as factors.
View Article and Find Full Text PDFDecay Rates of Maternal Tetanus, Diphtheria, and Pertussis Antibody Levels in Early and Moderate-to-Late Preterm and Term Infants at Birth and at Two Months.
Open Forum Infect Dis
January 2025
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
A post hoc analysis of maternally derived antibodies at birth and age 2 months following second trimester maternal Tdap vaccination between 20 and 24 weeks' gestational age (GA) showed a faster decay rate of Tdap-related immunoglobulin G in early preterms born before 32 weeks' GA compared with moderate-to-late preterms and full-terms. This is different from previous studies and merits further research.
View Article and Find Full Text PDFSafety, Efficacy, and Effectiveness of Maternal Vaccination against Respiratory Infections in Young Infants.
Semin Respir Crit Care Med
December 2024
South Africa Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Lower respiratory tract infection (LRTI) is a major cause of neonatal morbidity and mortality worldwide. Maternal vaccination is an effective strategy in protecting young infants from LRTI, particularly in the first few months after birth when infant is most vulnerable, and most primary childhood vaccinations have not been administered. Additionally, maternal vaccination protects the mother from illness during pregnancy and the postnatal period, and the developing fetus from adverse outcomes such as stillbirth and prematurity.
View Article and Find Full Text PDFSafety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda.
Lancet Glob Health
January 2025
Centre for Neonatal and Paediatric Infection and Vaccine Institute, City St George's, University of London, London, UK; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda; UK Health Security Agency, Salisbury, UK.
Background: Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!